An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Note that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...